Abilify available in two new formulations

February 13, 2006

Bristol-Myers Squibb and Otsuka Pharmaceutical announced two newly available formulations of Abilify (aripiprazole)-a 2-mg tablet strength and a nonrefrigerated oral solution (1 mg/ml). The 2-mg tablet equips physicians with another dosage strength to help them titrate patients to an effective dose.

Abilify available in two new formulations

Bristol-Myers Squibb and Otsuka Pharmaceutical announced two newly available formulations of Abilify (aripiprazole)-a 2-mg tablet strength and a nonrefrigerated oral solution (1 mg/ml). The 2-mg tablet equips physicians with another dosage strength to help them titrate patients to an effective dose. The nonrefrigerated oral solution allows greater convenience for adults who are unable to swallow or have difficulty swallowing tablets. Abilify is indicated for the treatment of schizophrenia, acute manic, and mixed episodes associated with bipolar I disorder and for maintaining efficacy in adults with bipolar I disorder with a recent manic or mixed episode who had been stabilized and then maintained for at least six weeks.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.